Exact Sciences reaffirms FY25 revenue forecast of $3.22B-$3.24B, in line with consensus of $3.23B
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 10 2025
0mins
Adjusted EBITDA Guidance: The company has revised its FY25 adjusted EBITDA forecast to $395M-$405M, down from the previous estimate of $470M-$480M.
Impact of Licensing Agreement: The updated guidance now includes the initial $75 million cash payment from a licensing agreement, which was not accounted for in earlier projections.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EXAS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EXAS
Wall Street analysts forecast EXAS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for EXAS is 100.20 USD with a low forecast of 78.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
1 Buy
19 Hold
0 Sell
Hold
Current: 102.300
Low
78.00
Averages
100.20
High
105.00
Current: 102.300
Low
78.00
Averages
100.20
High
105.00
About EXAS
Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Abbott Laboratories Q4 2025 Results and Future Outlook
- Earnings Miss: Abbott's Q4 2025 revenue of $11.5 billion fell short of Wall Street's $11.8 billion expectation, resulting in a nearly 10% drop in stock price, reflecting investor disappointment over the nutrition segment's performance.
- Profitability Improvement: Despite the revenue miss, Abbott's adjusted diluted EPS rose 12% year-over-year, meeting analyst expectations, indicating resilience in profitability, with a projected recovery in the nutrition business expected in the second half of 2026.
- Optimistic Growth Outlook: Abbott anticipates accelerated overall revenue growth in 2026, providing guidance of 6.5% to 7.5% organic sales growth and adjusted diluted EPS of $5.55 to $5.80, showcasing the company's confidence in future performance.
- Acquisition Potential: Abbott plans to close its acquisition of Exact Sciences in Q2 2026, which is expected to introduce a new growth vertical for the company, particularly in early cancer detection, potentially becoming a key driver of strategic transformation.
Continue Reading
Abbott Reports Disappointing Q4 Revenue, Stock Plummets
- Revenue Decline: Abbott's Q4 revenue of $11.5 billion fell short of Wall Street's $11.8 billion expectation, resulting in a nearly 10% stock drop, indicating investor disappointment with the company's performance.
- Nutrition Segment Challenges: CEO Robert Ford highlighted in the earnings call that higher manufacturing costs in the nutrition segment suppressed demand, reflecting increasing price sensitivity among consumers that impacted overall results.
- Future Growth Outlook: Abbott anticipates accelerated revenue growth in 2026, providing guidance of 6.5% to 7.5% organic sales growth, with adjusted EPS projected between $5.55 and $5.80, indicating a 10% year-over-year increase.
- Strategic Acquisition Plans: Abbott expects to close its acquisition of Exact Sciences in Q2 2026, with Ford believing this deal will introduce a new growth vertical for the company, potentially transforming its position in the early cancer detection market.
Continue Reading